

Duloxetine Delayed-Release Capsules

DEFINITION

Duloxetine Delayed-Release Capsules contain an amount of Duloxetine Hydrochloride equivalent to NLT 90.0% and NMT 110.0% of the labeled amount of duloxetine ($C_{18}H_{19}NOS$).

IDENTIFICATION

Change to read:

- **A. [▲]SPECTROSCOPIC IDENTIFICATION TESTS** (197), *Infrared Spectroscopy*: **197F[▲]** (CN 1-May-2020)

Buffer: 6.9 g/L of monobasic sodium phosphate in water adjusted with 5 N sodium hydroxide to a pH of 7.5

Spectral range: 1650 cm^{-1} to 900 cm^{-1}

Standard: 1 mg/mL of USP Duloxetine Hydrochloride RS in methylene chloride. Shake the contents, and sonicate for 1 min. Transfer 15 mL of filtrate into a separatory funnel, and add 15 mL of Buffer. Collect the organic layer, and evaporate to dryness. Redissolve the residue with a few drops of methylene chloride, and transfer to a potassium bromide or sodium chloride plate. Allow it to dry.

Sample: 1 mg/mL of duloxetine, from the contents of NLT 10 Capsules in methylene chloride. Proceed as directed in the Standard.

Acceptance criteria: Meet the requirements

- **B.** The retention time of the major peak of the Sample solution corresponds to that of the Standard solution, as obtained in the Assay.

ASSAY

Change to read:

PROCEDURE

Protect solutions of duloxetine from light.

Buffer A: 3.4 g/L of [▲]monobasic potassium phosphate[▲] (ERR 1-Jun-2019) in water. To 1 L of this solution add 15 mL of triethylamine, and adjust with phosphoric acid to a pH of 5.5.

Buffer B: 0.2 g/L of [▲]monobasic ammonium phosphate[▲] (ERR 1-Jun-2019) and 4.5 g/L of dibasic potassium phosphate in water. Adjust with phosphoric acid to a pH of 8.0.

Mobile phase: Methanol, tetrahydrofuran, and Buffer A (323:90:587)

Diluent: Methanol and Buffer B (50:50)

System suitability solution: 0.1 mg/mL of USP Duloxetine Hydrochloride RS, 0.05 mg/mL of α -naphthol, 0.01 mg/mL of USP Duloxetine Related Compound F RS, and 0.025 mg/mL of USP Duloxetine Related Compound H RS in Diluent. [NOTE—Add 1 mL of methanol before diluting to volume to assist with dissolving contents. Duloxetine related compound H is used for peak identification purposes in this solution.]

Standard solution: 0.1 mg/mL of USP Duloxetine Hydrochloride RS in Diluent

Sample solution: Nominally 0.1 mg/mL of duloxetine from the contents of NLT 5 Capsules, in Diluent

Chromatographic system

(See *Chromatography* (621), *System Suitability*.)

[NOTE—It is recommended to preheat the Mobile phase to 45°.]

Mode: LC

Detector: UV 230 nm

Column: 4.6-mm \times 7.5-cm; 3- or 3.5- μ m packing L7

Column temperature: 45°

Flow rate: 1.5 mL/min

Injection volume: 10 μ L

Run time: 6 times the retention time of duloxetine
System suitability

Samples: System suitability solution and Standard solution
[NOTE—See Table 2 in *Organic Impurities* for relative retention times.]

Suitability requirements

Resolution: NLT 1.6 between duloxetine and duloxetine related compound F; NLT 2 between α -naphthol and duloxetine related compound H, *System suitability solution*

Relative standard deviation: NMT 1.5%, *Standard solution*

Analysis

Samples: Standard solution and Sample solution

Calculate the percentage of the labeled amount of duloxetine ($C_{18}H_{19}NOS$) in the portion of Capsules taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times (M_{r1}/M_{r2}) \times 100$$

r_U = peak response from the Sample solution

r_S = peak response from the Standard solution

C_S = concentration of USP Duloxetine Hydrochloride RS in the Standard solution (mg/mL)

C_U = nominal concentration of duloxetine in the Sample solution (mg/mL)

M_{r1} = molecular weight of duloxetine free base, 297.42

M_{r2} = molecular weight of duloxetine hydrochloride, 333.88

Acceptance criteria: 90.0%–110.0%

PERFORMANCE TESTS

Change to read:

DISSOLUTION (711)

Test 1

Acid stage

Acid stage medium: 0.1 N hydrochloric acid VS; 1000 mL

Apparatus 1: 100 rpm

Time: 2 h

Buffer stage

Buffer stage medium: pH 6.8 phosphate buffer; 1000 mL

Apparatus 1: 100 rpm

Time: 60 min for Capsules containing 20% w/w pellets; 90 min for Capsules containing 32% w/w pellets

Buffer A and Mobile phase: Proceed as directed in the Assay.

Standard stock solution: 0.28 mg/mL of USP Duloxetine Hydrochloride RS, equivalent to 0.25 mg/mL of duloxetine, in Buffer stage medium. Use a small amount of methanol, not exceeding 2% of the final volume, to dissolve duloxetine.

Acid stage standard solution: 0.0023 mg/mL of USP Duloxetine Hydrochloride RS, equivalent to 0.002 mg/mL of duloxetine, from the Standard stock solution diluted with Buffer stage medium

Buffer stage standard solution: 0.023 mg/mL of USP Duloxetine Hydrochloride RS, equivalent to 0.02 mg/mL of duloxetine, from the Standard stock solution diluted with Buffer stage medium

Sample solution: After 2 h in the Acid stage medium, pass a portion of the solution under test through a suitable filter. Transfer the basket containing the pellets to the vessel containing the Buffer stage medium. After the appropriate time in the Buffer stage medium, pass a

portion of the solution under test through a suitable filter.

Chromatographic system

(See *Chromatography* (621), *System Suitability*.)

Mode: LC

Detector: UV 230 nm

Column: 4.6-mm × 7.5-cm; 3- or 3.5-μm packing L7

Column temperature: 45°

Flow rate: 1.5 mL/min

Injection volume: 10 μL

System suitability

Sample: *Acid stage standard solution*

[NOTE—The relative retention times for duloxetine and α-naphthol are 1.0 and 1.4, respectively.]

Suitability requirements

Tailing factor: NMT 1.5

Relative standard deviation: NMT 2.0%

Analysis

Samples: *Acid stage standard solution*, *Buffer stage standard solution*, and *Sample solution*

Calculate the concentration of duloxetine in the *Acid stage medium* (C_1):

$$\text{Result} = (r_U/r_S) \times C_S \times (M_{r1}/M_{r2})$$

- r_U = peak response of duloxetine from the *Sample solution*
 r_S = peak response of duloxetine from the *Acid stage standard solution*
 C_S = concentration of USP Duloxetine Hydrochloride RS in the *Acid stage standard solution* (mg/mL)
 M_{r1} = molecular weight of duloxetine free base, 297.42
 M_{r2} = molecular weight of duloxetine hydrochloride, 333.88

Calculate the equivalent concentration of duloxetine from α-naphthol in the *Acid stage medium* (C_2):

$$\text{Result} = (r_U/r_S) \times C_S \times (M_{r1}/M_{r2}) \times (M_{r1}/M_{r3})$$

- r_U = peak response of α-naphthol from the *Sample solution*
 r_S = peak response of duloxetine from the *Acid stage standard solution*
 C_S = concentration of USP Duloxetine Hydrochloride RS in the *Acid stage standard solution* (mg/mL)
 M_{r1} = molecular weight of duloxetine free base, 297.42
 M_{r2} = molecular weight of duloxetine hydrochloride, 333.88
 M_{r3} = molecular weight of α-naphthol, 144.17

Calculate the percentage of the labeled amount of duloxetine dissolved in the *Acid stage medium* (Q_A):

$$\text{Result} = (C_1 + C_2) \times V \times (1/L) \times 100$$

- C_1 = concentration of duloxetine in the *Acid stage medium* (mg/mL)
 C_2 = equivalent concentration of duloxetine from α-naphthol in the *Acid stage medium* (mg/mL)
 V = volume of *Medium*, 1000 mL
 L = label claim of duloxetine (mg/Capsule)

Calculate the percentage of the labeled amount of duloxetine dissolved in the *Buffer stage medium*:

$$\text{Result} = [(r_U/r_S) \times (C_S/L) \times V \times (M_{r1}/M_{r2}) \times 100] + Q_A$$

- r_U = peak response of duloxetine from the *Sample solution*
 r_S = peak response of duloxetine from the *Buffer stage standard solution*
 C_S = concentration of USP Duloxetine Hydrochloride RS in the *Buffer stage standard solution* (mg/mL)
 L = label claim (mg/Capsule)
 V = volume of *Medium*, 1000 mL
 M_{r1} = molecular weight of duloxetine free base, 297.42
 M_{r2} = molecular weight of duloxetine hydrochloride, 333.88
 Q_A = percentage of the labeled amount of duloxetine dissolved in the *Acid stage medium*

Tolerances

Acid stage: No individual unit releases more than 10% of the labeled amount of duloxetine in 2 h.

Buffer stage

For Capsules containing 20% w/w pellets: NLT 75% (Q) of the labeled amount of duloxetine is dissolved in 60 min.

For Capsules labeled to contain 32% w/w pellets: NLT 75% (Q) of the labeled amount of duloxetine is dissolved in 90 min.

Test 2: If the product complies with this test, the labeling indicates that it meets USP *Dissolution Test 2*.

Protect solutions of duloxetine from light.

Acid stage

Acid stage medium: 0.1 N hydrochloric acid VS; 750 mL

Apparatus 2: 100 rpm

Time: 2 h in *Acid stage medium*

Buffer stage

Buffer stage medium: pH 6.8 phosphate buffer (after 2 h, add 250 mL of 76 g/L of tribasic sodium phosphate, previously heated to 37 ± 0.5°, to the *Acid stage medium*); 1000 mL

Apparatus 2: 100 rpm

Time: 3 h in *Buffer stage medium*. The time in *Buffer stage medium* includes the time in *Acid stage medium*.

Solution A: A mixture of triethylamine and water prepared as follows. Add 15 mL of triethylamine to 1 L of water and adjust with phosphoric acid to a pH of 2.5 ± 0.05.

Mobile phase: Acetonitrile and *Solution A* (40:60)

Diluent: 0.1 N hydrochloric acid VS and 76 g/L of tribasic sodium phosphate (75:25)

Standard stock solution: 0.46 mg/mL of USP Duloxetine Hydrochloride RS, equivalent to 0.4 mg/mL of duloxetine, prepared as follows. Transfer a suitable amount of USP Duloxetine Hydrochloride RS to an appropriate volumetric flask and dissolve in 50% of the final flask volume of *Mobile phase*. Dilute with *Mobile phase* to volume.

Standard solution: 0.046 mg/mL of USP Duloxetine Hydrochloride RS, equivalent to 0.04 mg/mL of duloxetine, from the *Standard stock solution* in *Diluent*

Acid stage sample solution and Buffer stage sample solution: Pass a portion of the solution under test through a suitable filter, and use the filtrate. [NOTE—A cannula-style filter with a 20-μm pore size may be suitable.]

Chromatographic system

(See *Chromatography* (621), *System Suitability*.)

Mode: LC

Detector: UV 290 nm

Column: 4.6-mm × 15.0-cm; 3-μm packing L1

Column temperature: 40°